Metastatic Castration-resistant Prostate Cancer Clinical Trials in San Antonio, Texas

9 studies are recruiting for metastatic castration-resistant prostate cancer in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

   This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   USA Clinical Trials, San Antonio, Texas

   Locations

   236 in total

   Run by

   Pfizer

   See if you can join NCT06629779 on ClinicalTrials.gov

2. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

   The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics, San Antonio, Texas

   Locations

   80 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04104776 on ClinicalTrials.gov

3. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

4. A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

   The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   15 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06067841 on ClinicalTrials.gov

5. A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

   The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRP…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   10 in total

   Run by

   Flare Therapeutics Inc.

   See if you can join NCT07719361 on ClinicalTrials.gov

6. Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

   Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation. Phase II: Further characterize the safety and tolerability of GVV858 in combination with…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START, San Antonio, Texas

   Locations

   15 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT07288359 on ClinicalTrials.gov

7. A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

   Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the drug is safe, increasing doses alone and in combination with darolutamide, whether it is effective …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USA Clinical Trials, San Antonio, Texas

   Locations

   13 in total

   Run by

   K36 Therapeutics, Inc.

   See if you can join NCT07103018 on ClinicalTrials.gov

8. A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

   This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   19 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT07244341 on ClinicalTrials.gov

9. A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

   Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their can…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Urology San Antonio, San Antonio, Texas

   Locations

   25 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT04729114 on ClinicalTrials.gov